Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Bevacizumab
- Brain Metastases
- Non -Small Cell Lung Cancer
- Sintilimab
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04213170
- Collaborators
- Not Provided
- Investigators
- Study Director: Likun Chen, doctor Sun Yat-sen University